Vycor Medical, Inc.
VYCO
$0.0679
-$0.0001-0.15%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 47.70% | 26.67% | -15.85% | -6.65% | 13.60% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 47.70% | 26.67% | -15.85% | -6.65% | 13.60% |
| Cost of Revenue | 37.62% | 13.93% | -11.56% | 20.13% | 12.90% |
| Gross Profit | 49.29% | 28.16% | -16.23% | -9.15% | 13.71% |
| SG&A Expenses | 13.64% | 31.35% | 4.10% | 6.32% | 0.90% |
| Depreciation & Amortization | 3.47% | 3.47% | 3.47% | 3.47% | 0.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.08% | 27.51% | 1.01% | 5.70% | 2.70% |
| Operating Income | 130.11% | -37.65% | -83.21% | -128.61% | 29.71% |
| Income Before Tax | 92.56% | -16.12% | -114.12% | -501.32% | 22.35% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 92.56% | -16.12% | -114.12% | -501.32% | 22.35% |
| Earnings from Discontinued Operations | 96.77% | 100.00% | 100.00% | 85.71% | -342.86% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 92.80% | -15.22% | -114.62% | -543.48% | 20.09% |
| EBIT | 130.11% | -37.65% | -83.21% | -128.61% | 29.71% |
| EBITDA | 173.88% | -88.35% | -71.42% | -87.45% | 35.44% |
| EPS Basic | 93.10% | -1.52% | -114.29% | -22.92% | 19.44% |
| Normalized Basic EPS | 94.12% | -10.00% | -114.29% | -700.00% | 22.73% |
| EPS Diluted | 93.10% | -1.52% | -116.67% | -22.92% | 19.44% |
| Normalized Diluted EPS | 94.12% | -10.00% | -116.67% | -700.00% | 22.73% |
| Average Basic Shares Outstanding | 2.29% | 0.84% | 0.00% | 0.31% | 0.29% |
| Average Diluted Shares Outstanding | 2.29% | 0.84% | -12.91% | 0.31% | 0.29% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |